Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Krystal Biotech ( ($KRYS) ) has issued an announcement. On May 16, 2025, Krystal Biotech held its Annual Meeting of Stockholders where key ...

Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Biotech firm Synthego files for bankruptcy despite a purchase agreement with Perceptive Advisors and plans for operational ...

Biotech, one of the Bay Area's most important industries, sprang up in five short decades. Here are the key moments to know ...

The Bay Area's biotech industry faces an uncertain future after 50 years. But industry leaders see a history of resilience ...